Deregulated transcription factors and poor clinical outcomes in cancer patients. (November 2022)

• Record Type: Journal Article
• Authors: Li, Yiwei; Azmi, Asfar S.; Mohammad, Ramzi M.
• Is Part Of: Seminars in cancer biology. Volume 86(2023)Part 3
• Page Start: 122
• Page End: 134
• Publication Date: 2022-11
• Subjects: Transcription factor -- Clinical outcome -- Cancer stem cell -- EMT -- Drug resistance; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2022.08.001
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: Transcription factors are a group of proteins, which possess DNA-binding domains, bind to DNA strands of promoters or enhancers, and initiate transcription of genes with cooperation of RNA polymerase and other co-factors. They play crucial roles in regulating transcription during embryogenesis and development. Their physiological status in different cell types is also important to maintain cellular homeostasis. Therefore, any deregulation of transcription factors will lead to the development of cancer cells and tumor progression. Based on their functions in cancer cells, transcription factors could be either oncogenic or tumor suppressive. Furthermore, transcription factors have been shown to modulate cancer stem cells, epithelial-mesenchymal transition (EMT) and drug response; therefore, measuring deregulated transcription factors is hypothesized to predict treatment outcomes of patients with cancers and targeting deregulated transcription factors could be an encouraging strategy for cancer therapy. Here, we summarize the current knowledge of major deregulated transcription factors and their effects on causing poor clinical outcome of patients with cancer. The information presented here will help to predict the prognosis and drug response and to design novel drugs and therapeutic strategies for the treatment of cancers by targeting deregulated transcription factors.